# A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

> **NCT00249808** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 1266 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Efalizumab - anti-CD11a recombinant human monoclonal antibody

## Key facts

- **NCT ID:** NCT00249808
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12-13
- **Primary completion:** 2007-01-25
- **Final completion:** 2007-01-25
- **Target enrollment:** 1266 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249808, "A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00249808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*